

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	Kind Attn.: Famroze Pochara Asst. Vice President
Date: August 9, 2017	
Re.: Press Release	

Dear Sir / Madam,

We enclose herewith a copy of press release dated August 9, 2017 titled "Zydus receives final approval from the USFDA for Diltiazem Hydrochloride Extended-Release Capsules USP."


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above



Zydus receives final approval from the USFDA for Diltiazem Hydrochloride Extended-Release Capsules USP

Ahmedabad, 9 August 2017

Zydus Cadila has received the final approval from the USFDA to market Diltiazem Hydrochloride Extended-Release Capsules USP in strengths of 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg. The drug is used in the treatment of hypertension (high blood pressure), angina (chest pain), and certain heart rhythm disorders. It will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The sales of Diltiazem Hydrochloride Capsules is estimated at \$191.1 million. *Source: IMS Health, IMS National Sales Perspective Audit, MAT June 2017, extracted August 2017.*

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
